Transforming growth factor beta–Smad signaling pathway

The **transforming growth factor beta–Smad signaling pathway** is a canonical signaling cascade in which ligands of the TGF-β superfamily (such as TGF-βs, activins, and nodal proteins) bind to specific cell surface serine/threonine kinase receptors (type I and type II), leading to phosphorylation and activation of intracellular Smad proteins[1][2][6]. Activated receptor-regulated SMADs (R-SMADs, including SMAD2 and SMAD3 in the case of TGF-β) form complexes with the common-mediator SMAD (co-SMAD, SMAD4) and translocate into the nucleus to regulate the transcription of target genes involved in cell proliferation, differentiation, apoptosis, immune regulation, extracellular matrix production, and development[1][2][6]. Dysfunction or dysregulation of this pathway is implicated in numerous diseases, notably cancer, fibrosis, and autoimmune conditions[3][6]. *Note: This entity represents an entire signaling pathway, not a discrete druggable target such as a single receptor, enzyme, or protein.*\nThe "Transforming growth factor beta–Smad signaling pathway" is **not** a single target molecule or receptor, but a signaling pathway composed of multiple interacting ligands, receptors (e.g., TGF-β receptors), and intracellular effectors (Smad proteins). Thus, it does not fit the format for a canonical therapeutic target used in pharmacological databases[1][2][6]. Individual components within this pathway, such as "Transforming growth factor beta receptor type I" (TGFBR1), "Transforming growth factor beta receptor type II" (TGFBR2), or specific Smad proteins (e.g., SMAD3), are considered drug targets, but the pathway as a whole is not[1][2][3][6].

Other names

TGF-β/Smad signaling pathwayTGF-beta–Smad pathwayTGFβ-Smad pathway